Company profile: Numab Therapeutics
1.1 - Company Overview
Company description
- Provider of antibody-based therapeutics for severe diseases, including chronic inflammation and cancer, leveraging a plug-and-play platform to predictably yield ready-to-develop multispecific biotherapeutics. Offerings include NM26 for atopic dermatitis, NM49 for cancer, and λ-Cap (stable human antibody fragments) and MATCH (modular scaffolding for multispecific formats) technologies.
Products and services
- MATCH™: A modular scaffolding technology that creates stable multispecific antibody formats with multiple binding specificities for therapeutic development
- NM26: A bi-specific antibody targeting IL-4Rα and IL-31 for treating atopic dermatitis and other type 2 inflammatory disorders
- λ-Cap™: A platform delivering highly stable human antibody variable region fragments for therapeutic use in antibody-based medicines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Numab Therapeutics
InflaRx
HQ: Germany
Website
- Description: Provider of therapeutics for acute and chronic inflammation targeting the C5a/C5aR pathway, including vilobelimab, a monoclonal antibody for chronic inflammatory diseases, oncology and critically ill COVID-19, authorized for emergency use by the FDA in hospitalized adults requiring invasive mechanical ventilation or ECMO, and INF904, an oral C5aR inhibitor in development for chronic spontaneous urticaria and hidradenitis suppurativa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InflaRx company profile →
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
BlueSphere Bio
HQ: United States
Website
- Description: Provider of TCXpress technology designed to unlock the potential of personalized T-cell therapy for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueSphere Bio company profile →
Ancora Pharma
HQ: United States
Website
- Description: Provider of immune system modulation therapeutics using synthetic carbohydrates in the United States, offering vaccines against bacterial, parasitic, and viral infectious diseases, as well as therapeutics to treat cardiovascular and metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ancora Pharma company profile →
Hawaii Biotech
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on R&D of prophylactic vaccines for infectious diseases, including recombinant subunit vaccines (dengue, West Nile, Zika, tick-borne flaviviruses), viral hemorrhagic fevers (Crimean-Congo), and coronaviruses (SARS-CoV-2, pan-beta). Offers the GPI-0100 adjuvant, a protein production platform for vaccine development, and small molecule therapeutics for anthrax intoxication and botulism (BoNT type A).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hawaii Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Numab Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Numab Therapeutics
2.2 - Growth funds investing in similar companies to Numab Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Numab Therapeutics
4.2 - Public trading comparable groups for Numab Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →